Injectable PrEP and other options are in the pipeline, and that makes clinical trials more complicated
Oct. 14, 2016
| By Mary Engel / Fred Hutch News Service
An injectable form of PrEP and other options are in the pipeline as the HIV field enters a new era of prevention. But such advances, as welcome as they are, come with a twist: They complicate the task of designing the clinical trials needed to test additional tools. Fred Hutch's Dr. Deborah Donnell explains.
Center's HIV Vaccine Trials Network and HIV research unit mark annual observance
May 17, 2012
Friday, May 18 is HIV Vaccine Awareness Day—time to reflect on the progress made in HIV prevention research and treatment and look ahead at ways of increasing community awareness and support.
As the home to the HIV Vaccine Trials Network (HVTN)—the largest clinical trials network for an HIV vaccine in the world—and the Statistical Center for HIV/AIDS Research and Prevention (SCHARP), the Hutchinson Center is on the frontline of the global fight to find a preventive vaccine against HIV.
Fred Hutch is proud to be an Equal Opportunity and VEVRAA Employer. We are committed to cultivating a workplace in which diverse perspectives and experiences are welcomed and respected. We do not discriminate on the basis of race, color, religion, creed, ancestry, national origin, sex, age, disability, marital or veteran status, sexual orientation, gender identity, political ideology, or membership in any other legally protected class. We are an Affirmative Action employer. We encourage individuals with diverse backgrounds to apply and desire priority referrals of protected veterans. Read the EEO is the Law poster here.